Sales

Five things for pharma marketers to know: Friday, November 18, 2016

Five things for pharma marketers to know: Friday, November 18, 2016

By

Chicago requires pharma rep to have licenses, Acorda CEO backs Califf to remain FDA commish, high-prescribing medicare docs are on the rise

Physicians still rely on medical journals but turn to the web when they have only 10 minutes

Physicians still rely on medical journals but turn to the web when they have only 10 minutes

By

Drugmakers can do a better job of organizing dosing information, safety information, and clinical data on their brand websites, a new survey found.

Five things for pharma marketers to know: Thursday, November 3, 2016

Five things for pharma marketers to know: Thursday, November 3, 2016

By

Sprout investors sue Valeant; FDA raises safety concerns for Cempra's experimental pneumonia drug; NHS gets approval to prescribe eribulin to breast cancer patients

Five things for pharma marketers to know: Wednesday, November 2, 2016

Five things for pharma marketers to know: Wednesday, November 2, 2016

By

Valeant to sell stomach-drug business for $10 billion; Pfizer reports growth in third quarter; sales of hep.-C drugs drive revenue down for Gilead Sciences

Five things for pharma marketers to know: Friday, October 28, 2016

Five things for pharma marketers to know: Friday, October 28, 2016

By

Repatha and Praluent launches described by analyst as waste of money; AstraZeneca halts trial for cancer drug; health exchange choices dwindle

Five things for pharma marketers to know: Tuesday, October 25, 2016

Five things for pharma marketers to know: Tuesday, October 25, 2016

By

Novartis' Entresto and Cosentyx miss sales forecasts; faith-based investor group urges pricing transparency; Amgen invests in digital health

Top 25 neurology products, based on 2016 sales forecasts

Top 25 neurology products, based on 2016 sales forecasts

MS drugs top the list, led by Teva's Copaxone, Biogen's Tecfida and Avonex, and Novartis' Gilenya.

Five things for pharma marketers to know: Thursday, October 20, 2016

Five things for pharma marketers to know: Thursday, October 20, 2016

By

Chicago to require pharma reps to track their calls; GlaxoSmithKline joins Instagram; Lilly receives accelerated approval for cancer drug

4 Ways Dwindling Pharma Sales Detailing Will Affect the Cloud

4 Ways Dwindling Pharma Sales Detailing Will Affect the Cloud

As the effectiveness of in-person detailing wanes, how will cloud-based content solutions adapt?

Best Professional Sales Tool of 2016

Best Professional Sales Tool of 2016

By

To break through and drive a high level of physician interaction, Havas Life Metro and Genentech created an interactive self-guided digital storytelling experience to explain the unique mechanism of action of Gazyva.

MM&M's 5 most popular stories in September 2016

MM&M's 5 most popular stories in September 2016

By

Physicians are seeking beyond-the-pill services from drugmakers; Novartis debunks misconception that only smokers get lung cancer; pharma's access to docs declines

Five things for pharma marketers to know: Thursday, September 22, 2016

Five things for pharma marketers to know: Thursday, September 22, 2016

By

Mylan CEO comes under fire at House Committee hearing; Abbott OxyContin reps went to great lengths to sell the pain pill; UnitedHealth drops Lantus

Five things for pharma marketers to know: Wednesday, September 21, 2016

Five things for pharma marketers to know: Wednesday, September 21, 2016

By

Drugmakers to remove incentives for sales reps marketing antibiotics; Mylan CEO defends EpiPen pricing; fitness trackers don't help people lose weight

Report: 3 tips for pharma to provide beyond-the-pill services

Report: 3 tips for pharma to provide beyond-the-pill services

By

Physicians are seeking beyond-the-pill services from drugmakers, but few sales reps shares details with docs about these programs, a new report finds.

Five things for pharma marketers to know: Thursday, August 25, 2016

Five things for pharma marketers to know: Thursday, August 25, 2016

By

Mylan offers additional copay assistance for EpiPen amid criticism; fewer doctors are seeing reps; two Copaxone patents are invalidated

Top 25 women's health products, ranked by 2016 forecasts

Top 25 women's health products, ranked by 2016 forecasts

Amgen's osteoporosis drug Prolia is the category leader, projected to bring in $992 million in sales in 2016.

Five things for pharma marketers to know: Thursday, July 28, 2016

Five things for pharma marketers to know: Thursday, July 28, 2016

By

Vertex says Orkambi is on the blockbuster track; Advent and CVC reportedly made offers to buy inVentiv Health; the FDA approves Sanofi's Adlyxin

Five things for pharma marketers to know: Monday, July 11, 2016

Five things for pharma marketers to know: Monday, July 11, 2016

By

Purdue Pharma reportedly knew about OxyContin trafficking; Amgen's Repatha approved for monthly dosing option; Clinton proposes new healthcare measures

Five things for pharma marketers to know: Friday, June 17, 2016

Five things for pharma marketers to know: Friday, June 17, 2016

By

Hillary Clinton receives more donations from pharma than republicans; biotech reps have highest salaries; NICE recommends Yervoy-Opdivo combo

Infographic: Merck's Keytruda versus Bristol-Myers Squibb's Opdivo

Infographic: Merck's Keytruda versus Bristol-Myers Squibb's Opdivo

Here, see side-by-side comparisons of the drugs spending on advertising, approval dates, and 2015 sales figures.

Five things for pharma marketers to know: Wednesday, May 25, 2016

Five things for pharma marketers to know: Wednesday, May 25, 2016

By By

Antidepressants are often used to treat conditions other than depression; the FDA delays decision on Duchenne drug; Lilly and Pfizer develop new painkiller

Five things for pharma marketers to know: Thursday, May 19, 2016

Five things for pharma marketers to know: Thursday, May 19, 2016

By

Novartis plans new trials for Entresto; U.S. spending on mental health topped $201 billion in 2013; the FDA approves Roche's immunotherapy drug

Top 20 autoimmune products, 2015

Top 20 autoimmune products, 2015

By

AbbVie's Humira is the top selling autoimmune drug in 2015, bringing in $10.6 billion in sales in the U.S. alone.

2016 Pharma Report: All the data in one place

2016 Pharma Report: All the data in one place

Learn more about the top therapeutic categories by sales, top companies by revenue, top drugs by sales, and more.

Five things for pharma marketers to know: Friday, April 29, 2016

Five things for pharma marketers to know: Friday, April 29, 2016

By

Harvoni and Sovaldi growth begins to slow; drugmakers spend billions to buy developers of cancer therapies; Valeant discloses new investigations

Rolling with the Punches as Marketing Evolves

Rolling with the Punches as Marketing Evolves

Some 30% of the physicians in the U.S. sold their practices, which in turn commensurately reduced the number of physicians who are willing and able to be called on by sales reps.

Five things for pharma marketers to know: Monday, April 11, 2016

Five things for pharma marketers to know: Monday, April 11, 2016

By

Valeant's missteps derailed Addyi; Biogen reportedly considers selling its hemophilia treatment portfolio; Roche's PD-LI inhibitor granted Priority Review

MannKind reworks commercial strategy for Afrezza

MannKind reworks commercial strategy for Afrezza

By

After buying back the rights to the therapy, the biopharmaceutical company is building a endocrinology sales force and hiring a new advertising agency.

Five things for pharma marketers to know: Tuesday, April 5, 2016

Five things for pharma marketers to know: Tuesday, April 5, 2016

By

Valeant terminates Addyi's sales force; the Treasury Department issues new tax-inversion rules; MannKind buys back its marketing rights to Afrezza

Drugmakers move to counteract expiring patents with new respiratory drugs

Drugmakers move to counteract expiring patents with new respiratory drugs

By

Symptom-driven care is falling out of fa­vor with lung-drug leaders increasingly interested in assigning optimal treatment approaches to patient conditions.

OPINION

Email Newsletters